Table 3. Risk of gastric cancer incidence by chronic atrophic gastritis, H. pylori infection and CagA seropositivity.
| Chronic atrophic gastritis | H. pylori infection | Sample (n) | Cases (n) | Crude incidence rate† | HR1 (95% CI)‡ | HR2 (95% CI)‡ |
|---|---|---|---|---|---|---|
| None | IgG−/CagA− | 4,555 | 5 | 10.42 | Ref | Ref |
| IgG+/CagA− | 1,984 | 2 | 9.54 | 0.79 (0.15–4.08) | ||
| IgG+/CagA+ | 2,295 | 14 | 58.13 | 5.05 (1.81–14.09) | ||
| Present | IgG−/CagA− | 205 | 0 | 0 | 3.45 (1.38–8.64) | Not estimable |
| IgG+/CagA− | 143 | 1 | 64.61 | 5.50 (0.63–47.57) | ||
| IgG+/CagA+ | 315 | 5 | 151.20 | 12.51 (3.57–43.22) |
Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.
†
Per 100,000 person-years.
‡
Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection.